Trevi Therapeutics, Inc.
nalbuphine ER
IPF-related chronic cough
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for nalbuphine ER in IPF-related chronic cough are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“the second Phase 3 trial in the second half of 2026”